{"id":14145,"date":"2019-06-19T10:51:17","date_gmt":"2019-06-19T10:51:17","guid":{"rendered":"http:\/\/cio.edu.umh.es\/?p=14145"},"modified":"2021-07-22T09:50:24","modified_gmt":"2021-07-22T07:50:24","slug":"pharmacogenetics-and-prediction-of-adverse-events-in-prescription-opioid-use-disorder-patients-2019-basic-clinical-pharmacology-toxicology-124-439-448","status":"publish","type":"post","link":"https:\/\/cio.umh.es\/en\/2019\/06\/19\/pharmacogenetics-and-prediction-of-adverse-events-in-prescription-opioid-use-disorder-patients-2019-basic-clinical-pharmacology-toxicology-124-439-448\/","title":{"rendered":"Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients (2019). Basic &#038; Clinical Pharmacology &#038; Toxicology, 124, 439-448."},"content":{"rendered":"<p><strong>Javier Muriel\u00a0<\/strong>(<em>Alicante Institute for Health and Biomedical Research<\/em>), <strong>C\u00e9sar Margarit <\/strong>(<em>Alicante-General Hospital<\/em>), <strong>Jordi Barrachina <\/strong>(<em>Occupational Observatory, Miguel Hern\u00e1ndez University of Elche<\/em>), <strong>Pura Ballester<\/strong>\u00a0(<em>Alicante Institute for Health and Biomedical Research<\/em>), <strong>Andrea Flor<\/strong> (<em>Alicante-General Hospital<\/em>), <strong>Domingo Morales<\/strong> (<em>Miguel Hern\u00e1ndez University of Elche<\/em>), <strong>Jos\u00e9 F. Horga<\/strong> (<em>Alicante-General Hospital<\/em>), <strong>Eduardo Fern\u00e1ndez\u00a0<\/strong>(<em>Miguel Hern\u00e1ndez University of Elche<\/em>)\u00a0and\u00a0<strong>Ana M. Peir\u00f3 <\/strong>(<em>Alicante-General Hospital<\/em>).<br \/>\n<strong>Abstract.<\/strong>\u00a0The threats involved in the long\u2010term opioid treatment of chronic non\u2010cancer pain (CNCP) have increased notably. Strategies to identify at\u2010risk patients are important because there is no clear evidence showing which screening or deprescription programmes are appropriate. Our aim was to evaluate the evidence provided by pharmacogenetics applied to predict an analgesic toxicity profile in prescription opioid use disorder (POUD) patients participating in an opioid deprescription programme. Pharmacogenetic markers were analysed in an observational, prospective deprescription programme for POUD patients (n = 88) treated for CNCP. It consisted of monitoring visits (baseline, follow\u2010up and final), opioid rotation or discontinuation and the recording of adverse events and suspected adverse drug reactions (ADRs). Variants in OPRM1 (A118G), ABCB1 (C3435T), COMT (G472A), OPRD1 (T921C) and ARRB2 (C8622T) genes were tested by real\u2010time PCR. Ethics committee approved the study. Wild\u2010type OPRM1\u2010AA genotype carriers reported a significantly higher number of adverse events than OPRM1\u2010AG\/GG (median [p25 75], 7 [5\u201011] vs 5 [3\u20109]), particularly gastrointestinal system events (90% vs 63%) such as nausea (33% vs 0%). Suspected ADRs (affecting 17% of the patients) were three times higher in males than in females (30% vs 11%). The deprescription programme was effective and safe, and it achieved a significant progressive reduction in the morphine equivalent daily dose, strong opioids and other analgesics\u2019 use, without causing any changes in pain intensity or opiate abstinence syndrome. OPRM1 gene polymorphisms could identify the risk of gastrointestinal adverse events in POUD patients. Deprescription programmes including pharmacogenetic analysis should be considered during the follow\u2010up of this population.<br \/>\n<strong>Keywords.\u00a0<\/strong>Adverse events; Chronic pain; Opioid use disorder; Pharmacogenetics; Prescription opioids<\/p>","protected":false},"excerpt":{"rendered":"<p>Javier Muriel\u00a0(Alicante Institute for Health and Biomedical Research), C\u00e9sar Margarit (Alicante-General Hospital), Jordi Barrachina (Occupational Observatory, Miguel Hern\u00e1ndez University of Elche), Pura Ballester\u00a0(Alicante Institute for Health and Biomedical Research), Andrea Flor (Alicante-General Hospital), Domingo Morales (Miguel Hern\u00e1ndez University of Elche), Jos\u00e9 F. Horga (Alicante-General Hospital), Eduardo Fern\u00e1ndez\u00a0(Miguel Hern\u00e1ndez University of Elche)\u00a0and\u00a0Ana M. Peir\u00f3 (Alicante-General Hospital).<br \/>\nAbstract.\u00a0The [&#8230;]<\/p>","protected":false},"author":3477,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_links_to":"","_links_to_target":""},"categories":[369888],"tags":[],"_links":{"self":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/posts\/14145"}],"collection":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/users\/3477"}],"replies":[{"embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/comments?post=14145"}],"version-history":[{"count":0,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/posts\/14145\/revisions"}],"wp:attachment":[{"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/media?parent=14145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/categories?post=14145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cio.umh.es\/en\/wp-json\/wp\/v2\/tags?post=14145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}